this post was submitted on 20 Jun 2025
13 points (100.0% liked)

Public Health

982 readers
132 users here now

For issues concerning:


๐Ÿฉบ This community has a broader scope so please feel free to discuss. When it may not be clear, leave a comment talking about why something is important.



Related Communities

See the pinned post in the Medical Community Hub for links and descriptions. link (!medicine@lemmy.world)


Rules

Given the inherent intersection that these topics have with politics, we encourage thoughtful discussions while also adhering to the mander.xyz instance guidelines.

Try to focus on the scientific aspects and refrain from making overly partisan or inflammatory content

Our aim is to foster a respectful environment where we can delve into the scientific foundations of these topics. Thank you!

founded 2 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[โ€“] jet@hackertalks.com 1 points 1 month ago* (last edited 1 month ago)

Always happy to share! I'm genuinely happy you read what i wrote!

KPD https://en.wikipedia.org/wiki/Ketosis-prone_diabetes ?

You might find this interesting Ketosis, ketoacidosis and very-low-calorie diets: putting the record straight - 2011

TLDR: DKA and Ketosis are distinct biological states, and eating carbohydrates does not provide a benefit in avoiding DKA. i.e. DKA is resolved with insulin and not injecting/consuming glucose.

Update - Above you said your on a SLGT2 inhibitor, which does decrease insulin levels, so there is a DKA risk with that medication by itself, with your KPD condition I agree its probably not great to combine SLGT2i medication and a strict ketogenic diet

3.5.2.2.2 Medications that increase ketoacidosis risk - SGLT2 inhibitors: These medications carry a risk of euglycaemic ketoacidosis. TCR alone cannot cause ketoacidosis, but it may enhance the risk posed by SGLT2i by lowering insulin concentrations because insulin inhibits ketone formation. SGLT2i-induced ketoacidosis may occur with normal BG concentrations, and this heightens the risk of ketoacidosis going unrecognised. It is worth noting that a VLCD (typically less than 50 g of carbohydrate a day) can produce a physiologically normal state of ketosis, that should not be confused with the pathological state of diabetic ketoacidosis. Despite recent literature supporting slight cardiovascular risk reduction and renal protection of SGLT2i, it is recommended that SGLT2i are used with caution in those adhering to a low carbohydrate eating plan. It is appropriate to stop SGLT2i in many cases, particularly in those adhering to a VLCD (30โ€“50 g/day). A GLP-1 agonist is a safer choice as a second-line agent after metformin. See Murray et al. [299] for an excellent review of the physiology of an LCD mimicking many effects of SGLT2i - From Ketogenic : The Science of Therapeutic Carbohydrate Restriction in Human Health